title: Passive multistate surveillance for neutropenia after use of cocaine or heroin possibly contaminated with levamisole.
abstract: OBJECTIVE
  To characterize the demographic, clinical, and epidemiologic features of levamisole-associated neutropenia in cocaine or heroin users.
  
  
  METHODS
  State health departments were recruited for participation when the Centers for Disease Control and Prevention (CDC) was notified of potential cases by a clinician, a health department official, or a poison center between October 15, 2009, and May 31, 2010. A case was defined as a person with an absolute neutrophil count less than 1,000 cells/μL (or a WBC count <2,000 cells/μL) and a self-reported history or laboratory confirmation of cocaine or heroin use. Health department officials abstracted data from medical charts, attempted a patient interview, and submitted data to CDC for descriptive analysis.
  
  
  RESULTS
  Of the 46 potential cases reported from 6 states, half met eligibility criteria and had medical chart abstractions completed (n=23; 50%). Of these, close to half of the patients were interviewed (n=10; 43%). The average age was 44.4 years; just over half were men (n=12; 52%). The majority of patients presented to emergency departments (n=19; 83%). More than half presented with infectious illnesses (n=12; 52%), and nearly half reported active skin lesions (n=10; 44%). The majority of interview respondents used cocaine greater than 2 to 3 times a week (n=9; 90%), used cocaine more than 2 years (n=6; 60%), and preferred crack cocaine (n=6; 60%). All were unaware of exposure to levamisole through cocaine and of levamisole's inherent toxicity (n=10; 100%).
  
  
  CONCLUSIONS
  Physicians should suspect levamisole exposure in patients using illicit drugs, cocaine in particular, who present with unexplained neutropenia. Most patients reported chronic cocaine use and were unaware of levamisole exposure. Cocaine use is more prevalent among men; however, our results identified a higher-than-expected proportion of female users with neutropenia, suggesting women may be at higher risk. Emergency physicians and practitioners are uniquely positioned to recognize these patients early during their hospital course, elucidate a history of cocaine or other drug exposure, and optimize the likelihood of confirming exposure by arranging for appropriate drug testing.
authors: Centers for Disease Control and Prevention. svagi@cdc.gov
authors: Sara J
authors: SJ
authors: Vagi
authors: Sophia
authors: S
authors: Sheikh
authors: Monica
authors: M
authors: Brackney
authors: Susan
authors: S
authors: Smolinske
authors: Brandon
authors: B
authors: Warrick
authors: Nicholas
authors: N
authors: Reuter
authors: Joshua G
authors: JG
authors: Schier
mesh_terms: D000328:Adult; D003042:Cocaine / Q000009:adverse effects; D019970:Cocaine-Related Disorders / Q000150:complications*; D004340:Drug Contamination / Q000706:statistics & numerical data; D005260:Female; D003932:Heroin / Q000009:adverse effects; D006556:Heroin Dependence / Q000150:complications*; D006801:Humans; D007407:Interviews as Topic; D007978:Levamisole / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D011159:Population Surveillance; D014481:United States / Q000453:epidemiology
chemical_list: D007978:Levamisole; D003932:Heroin; D003042:Cocaine
references: JAMA. 2011 Apr 27;305(16):1657-8
references: 21521846
references: J Anal Toxicol. 2011 Oct;35(8):545-50
references: 22004673
references: Clin Toxicol (Phila). 2011 Dec;49(10):910-41
references: 22165864
references: J Infect Dis. 2002 Mar 1;185(5):701-5
references: 11865430
references: Biopharm Drug Dispos. 1986 Jan-Feb;7(1):71-89
references: 3754161
references: Harm Reduct J. 2009 Nov 17;6:30
references: 19919709
references: Ann Intern Med. 2007 May 1;146(9):657-65
references: 17470834
references: Clin Toxicol (Phila). 2012 Apr;50(4):231-41
references: 22455354
references: Ann Intern Med. 2010 Jun 1;152(11):758-9
references: 20513844
references: Arch Intern Med. 1999 Feb 22;159(4):369-74
references: 10030310
references: Health Serv Res. 2000 Apr;35(1 Pt 1):153-69
references: 10778828
references: J Psychoactive Drugs. 1993 Jul-Sep;25(3):207-21
references: 8258759
references: J Leukoc Biol. 2005 Dec;78(6):1198-203
references: 16204638
references: Clin Pharmacol Ther. 2010 Sep;88(3):408-11
references: 20668440
references: J Viral Hepat. 2011 Jul;18(7):e381-93
references: 21692951
references: Ann Intern Med. 2009 Feb 17;150(4):287-9
references: 19153405
references: Am J Health Syst Pharm. 1999 Dec 15;56 Suppl 5:S5-8
references: 10613380
references: J Am Acad Dermatol. 2010 Sep;63(3):530-5
references: 20304523
references: MMWR Morb Mortal Wkly Rep. 2009 Dec 18;58(49):1381-5
references: 20019655
references: Arch Dermatol. 2010 Nov;146(11):1320-1
references: 21079086
references: Clinics (Sao Paulo). 2009;64(9):857-66
references: 19759879